Corgenix Medical Corp. has entered into a collaboration with Eli Lilly and Co. to develop diagnostic technology to support a Lilly oncology program. The two companies will collaborate to further advance this diagnostic technology originally developed by Lilly. Financial terms were not disclosed.
 
“We are very pleased to enter into this new and exciting collaboration with Lilly,” said Douglass Simpson, president and chief executive officer of Corgenix, “This relationship strengthens our company’s program of strategic alliances in key areas of laboratory and research medicine. The Lilly collaboration in particular opens a new door for Corgenix as we continue to explore this technology in global clinical research as potential new technology to meet the needs of oncology clinicians worldwide.”
 
The collaboration with Lilly is part of Corgenix’ recently expanded Contract Services Business Unit for contract product development, technology application and manufacturing for the healthcare and biotechnology industries.